Neurological research · 2025
Moderate dietary flavonoid intake associated with lower prevalence of Parkinson's disease: data from the NHANES 2007-2010 and 2017-2018.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gong Shanshan, Fei Yuchang
Аннотация
OBJECTIVE: To investigate the relationship between dietary flavonoids and the prevalence of PD.
METHODS: We used data from the 2007-2010 and 2017-2018 National Health and Nutrition Examination Survey (NHANES). Dietary flavonoid intake was assessed through a two-day, 24-hour dietary recall method, and PD diagnosis was ascertained by the presence of 'Anti-Parkinson agents' among the reported prescription medications. Logistic regression, subgroup, and restricted cubic spline (RCS) models were employed to analyze the connection between dietary flavonoids and PD prevalence.
RESULTS: Our study revealed a correlation between the consumption of dietary total flavonoids, flavan-3-ols, and flavonols, and PD risk. Subgroup analysis indicated a negative correlation of dietary flavan-3-ols and total flavonoids with PD risk only among non-obese participants. Furthermore, our analysis using RCS demonstrated a nonlinear association between dietary flavonoids, flavan-3-ols, flavonols, and PD prevalence. We found that the optimal intake of total flavonoids, flavan-3-ols and flavonols wase 403.65 mg/day,346 mg/day and 26.74 mg/day, respectively. Above these thresholds, the risk of developing PD is elevated.
CONCLUSIONS: Our study highlights a significant association between moderate dietary intake of total flavonoids, flavan-3-ols, and flavonols, and a reduced risk of PD. Our work may provide new therapeutic ideas for the prevention and treatment of PD and provide dietary flavonoid intake recommendations for PD patients.
METHODS: We used data from the 2007-2010 and 2017-2018 National Health and Nutrition Examination Survey (NHANES). Dietary flavonoid intake was assessed through a two-day, 24-hour dietary recall method, and PD diagnosis was ascertained by the presence of 'Anti-Parkinson agents' among the reported prescription medications. Logistic regression, subgroup, and restricted cubic spline (RCS) models were employed to analyze the connection between dietary flavonoids and PD prevalence.
RESULTS: Our study revealed a correlation between the consumption of dietary total flavonoids, flavan-3-ols, and flavonols, and PD risk. Subgroup analysis indicated a negative correlation of dietary flavan-3-ols and total flavonoids with PD risk only among non-obese participants. Furthermore, our analysis using RCS demonstrated a nonlinear association between dietary flavonoids, flavan-3-ols, flavonols, and PD prevalence. We found that the optimal intake of total flavonoids, flavan-3-ols and flavonols wase 403.65 mg/day,346 mg/day and 26.74 mg/day, respectively. Above these thresholds, the risk of developing PD is elevated.
CONCLUSIONS: Our study highlights a significant association between moderate dietary intake of total flavonoids, flavan-3-ols, and flavonols, and a reduced risk of PD. Our work may provide new therapeutic ideas for the prevention and treatment of PD and provide dietary flavonoid intake recommendations for PD patients.